Gadolinium-based contrast can provide additional valuable information for many MRI or MRA examinations and is commonly used to highlight specific body regions or vascular systems.

OAI has closely monitored new findings in the last year regarding the disease known as Nephrogenic Systemic Fibrosis or Nephrogenic Fibrosing Dermopathy (NSF/NFD), which may occur in rare instances in patients with moderate to end-stage kidney disease after they have had a Magnetic Resonance Imaging (MRI) or Magnetic Resonance Angiography (MRA) scan with a gadolinium-based contrast agent.

To ensure the highest quality service and care, OAI has adopted the screening guidelines recommended by the American College of Radiology (ACR) regarding administration of contrast during an MRI or MRA exam.

When scheduling your appointment you will be asked if you have any of the following conditions:

• Kidney problems/renal disease
• Hepatic disease/liver transplant/pending liver transplant
• On prescription medication for hypertension
• On prescription medication for diabetes
• Age 60 or older

If any of the above risk factors apply, OAI will request a blood test to determine your BUN/Creatinine level and estimated GFR. The lab results must be within the last forty-five (45) days.

If your GFR is lower than 60, the radiologist will review your medical history, evaluate the risks and benefits of contrast administration, and discuss the situation with your ordering physician if deemed necessary. OAI staff will explain the radiologist’s decision at the time of your appointment.

As an added service OAI is now licensed to use the iSTAT® blood analysis device. If it is necessary to complete a blood test at the time of your appointment, OAI can provide a quick, economical, lab quality test in just minutes.